As of November 7, 2026, Cabaletta Bio, Inc. is a publicly traded company (Nasdaq: CABA); its largest reported holder is Bain Capital Life Sciences Opportunities III, LP, with 9.99% on Schedule 13G/A of August 14, 2026, then Adage Capital (8.43%) (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Cabaletta Bio, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Cabaletta Bio, Inc. a real, registered company?
- Cabaletta Bio, Inc. files with the SEC under CIK 1759138 (its SEC filings).
- Its shares are listed under the ticker CABA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Philadelphia, Pennsylvania, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under CABALETTA BIO INC in our court records and SEC 8-K records (as of 2026-11-07).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names T. Rowe Price (filed 2026-11-06).
Who are Cabaletta Bio, Inc.'s owners and officers?
Cabaletta Bio, Inc.: incorporated in Delaware; business address in Philadelphia, Pennsylvania; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-11-06).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-06 | T. Rowe Price Investment Management, Inc. | 8% |
| Schedule 13G/A, 2026-11-06 | T. Rowe Price Investment Management, Inc. | 13.1% |
| Schedule 13G/A, 2026-10-30 | Vanguard Capital Management | 3.79% |
| Schedule 13G/A, 2026-10-27 | Blackrock, Inc. | 7.7% |
| Schedule 13G/A, 2026-08-14 | T. Rowe Price Investment Management, Inc. | 11.6% |
| Schedule 13G/A, 2026-08-14 | Bain Capital Life Sciences Opportunities Iii, LP | 9.99% |
| Schedule 13G/A, 2026-08-14 | Cormorant Asset Management, LP | 5.95% |
| Schedule 13G/A, 2026-08-12 | Adage Capital Management, L.P. | 8.43% |
| Schedule 13G, 2026-08-12 | Norges Bank | 5.38% |
| Schedule 13G, 2026-07-31 | Vanguard Capital Management | 5.08% |
| Schedule 13G, 2026-07-27 | Blackrock, Inc. | 5.9% |
| Schedule 13G/A, 2026-07-23 | Millennium Management LLC | 1.3% |
Questions about who owns Cabaletta Bio, Inc.
Who owns Cabaletta Bio, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Cabaletta Bio, Inc.: Bain Capital Life Sciences Opportunities Iii, LP (9.99%, Schedule 13G/A, filed 2026-08-14), Adage Capital Management, L.P. (8.43%, Schedule 13G/A, filed 2026-08-12), T. Rowe Price Investment Management, Inc. (8%, Schedule 13G/A, filed 2026-11-06), Blackrock, Inc. (7.7%, Schedule 13G/A, filed 2026-10-27) and Cormorant Asset Management, LP (5.95%, Schedule 13G/A, filed 2026-08-14); 1 more is listed above.
Who are the largest shareholders of Cabaletta Bio, Inc.?
By the share each holder's latest filing reports, the largest holders of Cabaletta Bio, Inc. on this page are Bain Capital Life Sciences Opportunities Iii, LP (9.99%), Adage Capital Management, L.P. (8.43%) and T. Rowe Price Investment Management, Inc. (8%).
When did Bain Capital Life Sciences Opportunities Iii, LP buy into Cabaletta Bio, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Bain Capital Life Sciences Opportunities Iii, LP on this page is the Schedule 13G/A, filed 2026-08-14, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Cabaletta Bio, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Cabaletta Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cabaletta Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Cabaletta Bio, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 1,394,483 shares (0.65% of shares outstanding), 1,031,483 held directly and 363,000 indirectly (Form 4, 2026-01-21).
- , a director: 154,205 shares (0.07% of shares outstanding), 147,205 held directly and 7,000 indirectly (Form 4, 2026-01-21).
- , the president and science: 31,312 shares (0.01% of shares outstanding) (Form 4, 2026-01-21).
- , a director: 22,725 shares (0.01% of shares outstanding), held indirectly through By Shawn Tomasello Consulting LLC (Form 4, 2026-01-21).
- , the chief commercial officer: 22,170 shares (0.01% of shares outstanding) (Form 4, 2026-01-21).
Shares outstanding: 215,720,392 as of 2026-10-30, from the company's latest SEC cover page.
How much has Cabaletta Bio, Inc. raised?
No fundraising or offering filing from Cabaletta Bio, Inc. is on file with us.
Keep reading
More on Cabaletta Bio, Inc. and the records around it.
Cabaletta Bio, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Bain Capital Life Sciences Opportunities III, LP also filed stake reports on 2 other companies: KYVERNA THERAPEUTICS, INC. (Aug 2026), CENTURY THERAPEUTICS, INC. (Nov 2025)
- Jennison Associates LLC also filed stake reports on 14 other companies: LENDINGTREE INC (Oct 2026), PALVELLA THERAPEUTICS INC (Oct 2026), REZOLUTE INC (Oct 2026)
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/cabaletta-bio